Lead program may fail in clinical development
IGC-AD1 is still in Phase 2, so efficacy or safety issues could stop commercialization.
- Scope
- IGC-AD1 and broader Alzheimer’s pipeline
- Materiality
- high
IGC Pharma, Inc.
IGC Pharma, Inc. is a U.S.-based clinical-stage pharmaceutical company focused on Alzheimer’s disease and related neurodegenerative conditions. Its lead program, IGC-AD1, is in Phase 2 testing for agitation in Alzheimer’s dementia, while the company also sells a small portfolio of white-label, private-label, and branded wellness products through its Life Sciences segment.
−537,2 %
48,7 %
−560,3 %
−5,5 %
1.28
0.68
| % | |
|---|---|
| Clinical-stage therapeutics | 0% Investigational Alzheimer’s and neurodegenerative disease drug candidates in preclinical and Phase 2 development. |
| Life Sciences consumer and white-label products | 100% Manufactured formulations, white-label products, and branded wellness items sold commercially. |
| Research and development services | 0% Internal clinical development, trial operations, and related scientific work supporting pipeline advancement. |
IGC Pharma sells primarily to commercial buyers of manufactured wellness and formulation products, while its core...
- Commercial formulation customersprimary
Buy white-label and private-label manufactured products for resale or distribution.
- Branded wellness consumerssecondary
Purchase holistic health and branded products through retail and online channels.
- Alzheimer’s patients and caregiversprimary
The end market for IGC-AD1 and future neurodegenerative therapies aimed at symptom relief.
- Healthcare partners and licenseesemerging
Potential collaborators that may help fund, develop, or commercialize pipeline assets.
IGC Pharma is headquartered in the United States and manufactures products in Vancouver, Washington, which is important...
- •Headquartered in the United States
- •Manufacturing and fulfillment tied to Vancouver, Washington
- •U.S. FDA oversight is central to pipeline commercialization
- •No country-level revenue split was disclosed in the excerpts
- •Facility disposition temporarily reduced production and shipments
IGC Pharma is prioritizing advancement of IGC-AD1 through Phase 2 clinical development while building a broader...
01
Complete Phase 2 development of IGC-AD1short-term
The lead asset is the main driver of future value and clinical validation.
02
Expand the Alzheimer’s pipelinemedium-term
A broader pipeline reduces single-asset dependence and improves partnering potential.
03
Preserve liquidity and access to capitalshort-term
The company remains loss-making and needs funding to sustain R&D and trials.
04
Use internal execution to lower trial costsmedium-term
Lower per-patient trial costs improve capital efficiency and extend runway.
IGC Pharma faces the typical risks of a clinical-stage biotech company: trial failure, regulatory delay, and the...
Dependence on external financing
The company has recurring losses and limited cash, so it relies on equity raises and other funding.
- Scope
- Operations, R&D, and working capital
- Materiality
- high
Competitive pressure in Alzheimer’s therapeutics
Larger pharmaceutical companies have more capital, development capacity, and commercialization reach.
- Scope
- Alzheimer’s agitation treatment market
- Materiality
- high
Customer and supplier concentration
A few customers and suppliers account for a meaningful share of activity, increasing disruption risk.
- Scope
- Life Sciences commercial business
- Materiality
- medium
Digital asset treasury volatility
Mark-to-market changes on ETP holdings can affect reported earnings and liquidity perception.
- Scope
- Treasury management
- Materiality
- medium
Revenue recognition under ASC 606
Affects quarterly revenue and gross margin comparability
Digital asset fair-value accounting
Can introduce non-operating volatility in net loss
Impairment of long-lived assets
Can materially reduce operating results in a period
Stock-based compensation and warrant valuation
Affects operating expenses and shareholder dilution analysis
IMAC Holdings, Inc.
BACK · Services-Specialty Outpatient Facilities, NEC
IMMUNIC, INC.
IMUX · Pharmaceutical Preparations
CG Oncology, Inc.
CGON · Biological Products, (No Diagnostic Substances)
IONIS PHARMACEUTICALS INC
IONS · Pharmaceutical Preparations
Ionis Pharmaceuticals is a U.S.-based biotechnology company focused on RNA-targeted medicines, using antisense chemistry to discover and develop therapies for serious diseases.
Aligos Therapeutics, Inc.
ALGS · Biological Products, (No Diagnostic Substances)
CalciMedica, Inc.
CALC · Pharmaceutical Preparations
: 28.4.2026